Article
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Cancer cell - 14 Aug 2023
Li Xiaoling, Wang Yunguan, Deng Su, Zhu Guanghui, Wang Choushi, Johnson Nickolas A, Zhang Zeda, Tirado Carla Rodriguez, Xu Yaru, Metang Lauren A, Gonzalez Julisa, Mukherji Atreyi, Ye Jianfeng, Yang Yuqiu, Peng Wei, Tang Yitao, Hofstad Mia, Xie Zhiqun, Yoon Heewon, Chen Liping, Liu Xihui, Chen Sujun, Zhu Hong, Strand Douglas, Liang Han, Raj Ganesh, He Housheng Hansen, Mendell Joshua T, Li Bo, Wang Tao, Mu Ping
Abstract excerpt
Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the mutational signatures of more than 70% of human cancers. However, the mechanism underlying how cancer cells hijack the APOBEC mediated mutagenesis machinery to promote tumor heterogeneity, and thereby foster therapy resistance remains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.